相关实验视频

Updated: Jul 5, 2025

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

UCHL1是一种潜在的分子指标和神经内分泌癌的治疗标

Shiqin Liu¹, Timothy Chai², Fernando Garcia-Marques³

¹Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiology, Stanford University, Palo Alto, CA, USA.

Cell reports. Medicine

|January 20, 2024

概括

在神经内分泌癌症中,乌比奎丁碳氧终端酶L1 (UCHL1) 的含量升高,导致瘤生长和转移. 抑制UCHL1显示为这些侵袭性癌症的治疗策略有前途.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

神经内分泌癌,包括前列腺癌和肺癌,往往呈现出不良预后和有限的治疗途径.
乌比基碳基终端酶L1 (UCHL1),一种二氧化酶,在患有神经内分泌癌症的患者中观察到水平升高.

研究的目的:

研究UCHL1在神经内分泌癌的进展中的作用.
评估UCHL1作为潜在的治疗标和神经内分泌癌的诊断标记.

主要方法:

在患者组织和血中评估UCHL1水平.
在临床前模型中研究了UCHL1损失对瘤生长和转移的影响.
研究了UCHL1的作用机制,其中包括POM121,p53,E2F1和c-MYC.
测试了UCHL1抑制剂LDN-57444及其与西斯普拉丁组合的疗效.

主要成果:

降低的UCHL1水平降低了瘤生长和抑制了转移.
发现UCHL1稳定了POM121,影响了E2F1和c-MYC的核运输,从而维持神经内分泌的分化并促进了癌症的进展.
抑制UCHL1,特别是LDN-57444,减缓了瘤生长和转移.
在临床前情况下,UCHL1抑制剂与西斯普拉丁的联合治疗显著延迟了瘤生长.

结论:

通过调节关键细胞通路,UCHL1在神经内分泌癌的进展中起着至关重要的作用.
UCHL1是一个有前途的治疗标,也是神经内分泌癌症诊断和治疗监测的潜在生物标志物.

关键词:

在UCHL1上.神经母细胞瘤的神经母细胞瘤神经内分泌癌细胞瘤.神经内分泌前列腺癌前列腺癌.核孔复合体是核孔复合体.小细胞肺癌是一种小细胞肺癌.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...